bioAffinity Technologies

04/03/2026

Evaluating pulmonary nodules often requires clinical judgment based on the results of independent diagnostic tests.

CyPath® Lung provides physicians with actionable results using flow cytometry and AI, adding an independent analysis of the lung microenvironment to determine the most appropriate next steps in patient care.

CyPath® Lung provides actionable results that help physicians determine whether “watchful waiting” is appropriate or more aggressive procedures are called for. Learn more: https://www.cypathlung.com/

04/02/2026

There’s still time to register.

bioAffinity Technologies’ live virtual physician roundtable featuring leading pulmonologists discussing real-world use of CyPath® Lung in clinical practice happens next week.

Hear case studies demonstrating how CyPath® Lung supports lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance.

Details: https://bit.ly/4sIGMzW

04/01/2026

bioAffinity Technologies (Nasdaq: BIAF) today announced that preliminary unaudited CyPath® Lung unit sales in Q1 2026 increased 146% year over year, exceeding internal projections and reflecting accelerating physician adoption and expanding clinical use of its noninvasive lung cancer diagnostic.

The continued growth highlights increasing recognition of CyPath® Lung’s potential role in lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance.

With an expanding U.S. addressable market and continued focus on physician site expansion, peer-to-peer education and clinical workflow integration, the company believes CyPath® Lung is well-positioned for continued commercial momentum.

Read more: https://bwnews.pr/418gmeX

04/01/2026

A Lung-RADS 4A result immediately raises concern.

A Lung-RADS 4A classification for a nodule found by imaging can raise concern for both the patient and physician but doesn’t necessarily require biopsy. In this case, the CyPath® Lung result was “Unlikely” malignancy, supporting surveillance instead of an invasive procedure. A follow-up scan showed the nodule was stable.

Watch the case study: https://bit.ly/4bfGjza

03/31/2026

Diagnostics play a critical role in improving patient outcomes, especially in lung cancer where early detection can make a life-saving difference.

Diagnosing Dx offers an insightful look at bioAffinity Technologies and the importance of our noninvasive test CyPath® Lung for the early detection of lung cancer, as well as our tests for asthma and COPD that are under development.

In this conversation, CEO Maria Zannes explores the importance of noninvasive diagnostics, the growing adoption and use of CyPath® Lung in clinical practice.

Thank you David Filby for the opportunity to discuss CyPath Lung® and its use by physicians for their patients at high risk for lung cancer and the exciting work underway to improve patient outcomes.

Watch here: https://bit.ly/3NVKsPK

In this episode of Diagnosing Dx, I’m joined by Maria Zannes, Chief Executive Officer and Director at bioAffinity Technologies.Maria shares her journey from ...

03/30/2026

GO2 for Lung Cancer is a leader in the fight against lung cancer. We are always proud to stand with them in support of early detection and improved patient outcomes. Even tho it was an overcast day in Dallas on Saturday, ~400 people signed up for the GO2 5K Walk/Run. Their fundraising and participation helps provide one-on-one assistance, screening, and treatment navigation, and fund the latest research to accelerate cures and change this disease from one of stigma to one of hope. Confronting lung cancer starts here!

03/27/2026

CyPath® Lung provides physicians with additional insight on the risk of malignancy, with actionable results to guide patient care. Patients benefit from noninvasive sample collection that they can do at home.

CyPath® Lung’s actionable results can lead to better shared discussions between patients and their doctors. https://www.cypathlung.com/

03/26/2026

Noninvasive lung cancer diagnostics are gaining momentum.

A recent article highlights how noninvasive CyPath® Lung helps physicians and their patients decide whether small pulmonary nodules should be biopsied or whether continued imaging is the better choice. Results of a clinical trial demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in high-risk patients with small pulmonary nodules less than 20mm.

With nearly 100% sales growth in 2025 and similar revenue growth forecast in 2026, bioAffinity Technologies is advancing CyPath® Lung for early-stage detection of the world's largest cancer killer.

Read more: https://bit.ly/4rSVgwd

Shares rose by 73% during the session with no immediate catalyst

03/26/2026

A pulmonary nodule found in a patient with recent breast cancer led to CyPath® Lung testing . A “Likely” malignancy result from CyPath® Lung led to discovery that the breast cancer returned, leading to treatment and later resolution of the nodule and recurrent breast cancer.

CyPath® Lung offers real-time guidance to help physicians navigate complex oncology cases. View the case study:

Dr. Gordon Downie shares a patient case study in which CyPath Lung detected a hidden recurrence of breast cancer that has metastasized to the lung.

03/25/2026

If you’re interested in learning about real-world patient cases and the benefits of clinical use of the noninvasive CyPath® Lung diagnostic test, bioAffinity Technologies (Nasdaq: BIAF) invites you to join a live virtual physician roundtable with a panel of leading pulmonologists.

Physicians will share case studies demonstrating how CyPath® Lung supports lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance. From identifying Stage 1A lung cancer when it is curative to helping patients avoid unnecessary invasive, risky and costly procedures, this session will provide practical insights for healthcare professionals.

Additional details and registration here: https://bit.ly/4sIGMzW

03/23/2026

CyPath® Lung achieved record results in 2025 as more physicians add it to their standard of care for patients with indeterminate pulmonary nodules. Revenue from the noninvasive lung cancer test rose 87% year over year, while the number of tests performed increased 99% compared to 2024.

Growth was fueled by expanding physician adoption, peer-to-peer engagement, and real-world patient case studies. These milestones validate the first phase of the company’s commercialization strategy and highlight the increasing clinical impact CyPath® Lung is having for physicians and patients alike.

Learn more from the recent release: https://bit.ly/4rz0ZXz

03/20/2026

A patient with a suspicious lung nodule was reluctant to proceed with a biopsy, leading his physician to order noninvasive CyPath Lung.

CyPath® Lung’s “Likely” malignancy in the lung result provided greater clarity, helping guide a shared decision to move forward with a biopsy.
With earlier detection, the patient received timely treatment.

CyPath® Lung supports informed conversations between physicians and patients when timing and certainty matter most. Watch the case study: https://bit.ly/4bvj8zI